Taysha Gene Therapies, Inc. TSHA Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Taysha Gene Therapies, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: Taysha Gene Therapies, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Taysha Gene Therapies, Inc.'s total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Taysha Gene Therapies, Inc.'s total liabilities & equity?
- Taysha Gene Therapies, Inc. (TSHA) reported total liabilities & equity of $300.35M in Q1 2026.
- How has Taysha Gene Therapies, Inc.'s total liabilities & equity changed year-over-year?
- Taysha Gene Therapies, Inc.'s total liabilities & equity increased by 117.1% year-over-year, from $138.36M to $300.35M.
- What is the long-term trend for Taysha Gene Therapies, Inc.'s total liabilities & equity?
- Over 5 years (2020 to 2025), Taysha Gene Therapies, Inc.'s total liabilities & equity has grown at a 5.8% compound annual growth rate (CAGR), from $258.88M to $343.32M.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.